This paper compares and analyzes findings from the 2007 and 2011 Life Underwriting Requirement surveys.
There were 135 participants in 2007, whereas 90 U.S. insurers completed the 2011 survey. Nearly all of the 50 largest insurers participated in both surveys.
After writing a comprehensive CE (continuing education) course on the late underwriting implications of childhood/adolescence cancer, it was clear to me that companies doing teleunderwriting need a specific drilldown questionnaire to adequately address this subject.
More and more childhood/adolescence cancer patients survive for decades after apparent cure. Many experience significant complications arising years to decade after completion of all treatment.
Here are a set of coronary artery disease slides from a lecture Hank presented recently. These slides provide a complete review of the pathology, symptoms, diagnosis, and management of coronary artery disease.
In the North American market, life insurers screen for one drug of abuse routinely. That drug, of course, is cocaine and we have been testing for it in both urine and oral fluid for many years.
However, cocaine is not the only abused drug that has attracted insurer interest. While nearly all carriers include cocaine testing in their urine profiles, both marijuana and methamphetamine are also under “surveillance” on some basis by certain carriers.
We have just posted the slides from Hank's recent lecture based on key findings from of the 2010 Older Age Underwriting Survey. There are many insights here into how American companies approach the risk screening and insurability assessment of applicants age 65 and over for life insurance.
The slides from Hank's lecture on Pharmacy (Rx) Profiles at the May 14 meeting of the Chicago Home Office Life and Health Underwriters Association are now posted. These slides cover a wide range of information about pharmaceuticals in underwriting; need-to-know information for mortality and morbidity underwriters worldwide.